NCT03812588View on ClinicalTrials.gov

Contact: Developing New Clinical Management Strategies

PHASE4CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 30, 2019

Primary Completion Date

May 27, 2020

Study Completion Date

August 1, 2021

Conditions
Major Depressive Disorder
Interventions
DRUG

Escitalopram

Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI) medication that appears to help with symptoms of depression by increasing the availability of specific chemicals in the brain.

DRUG

Placebo

A placebo (or dummy pill) is an inert (inactive) substance, typically a tablet, capsule or other dose form that does not contain an active drug ingredient.

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

All Listed Sponsors
collaborator

University of Haifa

OTHER

lead

New York State Psychiatric Institute

OTHER

NCT03812588 - Contact: Developing New Clinical Management Strategies | Biotech Hunter | Biotech Hunter